Allied Market Research

2024

Tick-borne Encephalitis Inactivated Vaccine Market

Tick-borne Encephalitis Inactivated Vaccine Market Size, Share, Competitive Landscape and Trend Analysis Report, by Virus Type and, by End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Tick-borne encephalitis vaccine is used against tick-borne encephalitis (TBE) virus, which spread by bites of virus-infected ticks, affecting brain and spinal cord. The major symptoms occurring as a result of TBE infection are headache, agitation, high temperature (fever), sickness (vomiting), and confusion.

The major factors that drive the growth of global tick-borne encephalitis vaccine, inactivated market is rise in prevalence of tick-borne encephalitis, especially in Europe, and increased government funding on healthcare facilities. In addition, increase in drug development owing to technological advancement in the medical sector fuels the market growth. However, high cost of vaccines is the major restraint of the market. On the contrary, untapped economies with unmet medical needs is anticipated to provide lucrative opportunities for market growth.

The report segments the global tick-borne encephalitis vaccine, inactivated market based on virus type, end user, and geography. On the basis of virus type, the market is categorized into European TBE virus, far eastern TBE virus, and Siberian TBE virus. In terms of end user, it is classified into pediatric vaccines, adult vaccines, and traveler vaccines. Regionally, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in the market include Pfizer Inc., Encephalitis Global, Inc., The Cochrane Collaboration, Sonic HealthPlus Pty Ltd., Superdrug Health Clinic, GlaxoSmithKline plc, Merck & Co., Inc., Baxter International Inc., London Travel Clinic, and Hawaii Biotech, Inc.

Key Benefits

  • The study provides an in-depth analysis of the global tick-borne encephalitis inactivated vaccine market and the current trends and future estimations to elucidate the imminent investment pockets.
  • The report presents quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the market based on product assists to understand the trends in the industry.
  • Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the industry.

Tick-borne Encephalitis Inactivated Vaccine Market Report Highlights

Aspects Details
icon_5
By Virus Type
  • European TBE Virus
  • Far Eastern TBE Virus
  • Siberian TBE Virus
icon_6
By End User
  • Pediatric Vaccines
  • Adult Vaccines
  • Traveler Vaccines
icon_7
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Turkey, Venezuela, Saudi Arabia, South Africa, Rest of LAMEA)
icon_8
Key Market Players

Pfizer Inc., Encephalitis Global, Inc., Merck & Co., Inc., Hawaii Biotech, Inc., GlaxoSmithKline plc, Baxter International Inc., The Cochrane Collaboration, Sonic HealthPlus Pty Ltd., Superdrug Health Clinic, London Travel Clinic

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Tick-borne Encephalitis Inactivated Vaccine Market

Global Opportunity Analysis and Industry Forecast, 2023-2032